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Our aim was to assess whether the presence of highly 
active effector T cells in atopic dermatitis (AD) is asso-
ciated with changes in the number and/or function of re-
gulatory T cells (Tregs). Flow cytometry was utilised to 
determine the percentage of CD4+CD25brightCD127–/low-
FOXP3+ and skin-homing CLA+CD4+CD25brightFOXP3+ 
Tregs in healthy controls and AD patients. The correla-
tion between disease severity and Treg percentages was 
estimated. Treg suppressor activity and cell proliferation 
were measured after T-cell stimulation. Significantly in-
creased percentages of Tregs were found in AD patients 
compared to healthy individuals, and significant correla-
tion between the frequency of Tregs and disease severity 
was also detected. The otherwise normal suppressor acti-
vity of Tregs decreased in the presence of Staphylococcus 
enterotoxin B (SEB). In conclusion, the continuous pre-
sence of SEB can trigger an acquired functional impair-
ment of Tregs in AD patients and the correlation between 
the increased frequency of Tregs and disease severity 
supports their important role in AD pathogenesis. Key 
words: atopic dermatitis; cutaneous lymphocyte-associated 
antigen; regulatory T cells; Staphylococcus enterotoxin B.
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Regulatory T cells are important contributors to periphe-
ral immune tolerance. Three main subgroups of these 
cells have been identified: T helper (Th) 3 cells, T regu-
latory type 1 (Tr1) cells, and CD4+CD25brightFOXP3+ T 
regulatory (Treg) cells (1). The latter Tregs participate in 
the regulation of the allergen-specific immune response, 
as well as suppressing antigen-presenting cells (APC), 
effector T cells, and mast cell function (2–4). 
Atopic dermatitis (AD) is a chronic inflammatory skin 
disease with a complex pathogenesis. The combination 
of genetic and acquired skin barrier dysfunctions as 
well as distorted innate and adaptive immune responses 
lead to the development of the characteristic clinical 
picture (5–9). The well characterised dysregulation 
of the adaptive immune system can be the result of 
altered immune suppression (3, 9–11). For this reason, 
the role of Tregs has been investigated intensely in AD 
(1, 12).  The functional disequilibrium of Tregs may 
also be predicted by the clinical evidence of AD-like 
symptoms (severe eczema, eosinophilia, elevated IgE 
levels, and food allergy) in IPEX syndrome (Immune 
dysregulation, Polyendocrinopathy, Enteropathy, X-
linked syndrome), where Tregs are absent due to genetic 
alterations in the FOXP3 gene (13). Recent studies have 
found evidence of an increase in the number of Tregs 
in AD, although only a small number of investigations 
have been conducted to functionally characterise these 
cells (14–16). Furthermore results show a discrepancy 
in characterising Treg functions that necessitate further 
studies in this regard.
The aim of the present study was to determine 
quantitative and functional changes of Tregs as well as 
skin-homing Tregs in AD, and to investigate whether 
these parameters could correlate with clinical severity. 
METHODS
Patients
Peripheral blood was obtained from 27 AD patients (mean 
age: 24 years, range 5–41) with moderate or severe clinical 
symptoms and high (>1,000 U/ml) serum IgE levels (mean IgE 
level 10,321 kU/l, range 1,122–65,463). All patients fulfilled 
the diagnostic criteria for Hanifin & Rajka (17). The severity 
of disease was determined by the Scoring Atopic Dermatitis 
(SCORAD) index (mean SCORAD: 44, range 18–68). Hyper 
IgE Syndrome (HIES) was excluded in all patients using the 
HIES clinical scoring system (18). Patients who were enrolled in 
the study had not been treated with oral glucocorticosteroids or 
other immunomodulatory agents for at least 4 weeks and had not 
received antihistamines and topical corticosteroids for at least 
4 days prior to sampling. Blood samples from 11 healthy age-
matched volunteers served as controls. All participants provided 
their written informed consent according to the Declaration of 
Helsinki principles. The study was approved by the local ethics 
committee of the University of Debrecen. 
Measurement of serum IgE level
Serum IgE levels were measured by using an enzyme-linked 
immunosorbent assay (Radim SpA, Pomezia (Rome), Italy) 
according to the manufacturer’s instructions.
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Cell preparations
Peripheral blood mononuclear cells (PBMCs) were isolated 
by Ficoll (Sigma-Aldrich, Munich, Germany) gradient centri-
fugation from heparinised blood. CD4+CD25+ Treg cells were 
separated by positive selection with a regulatory T-cell isolation 
kit (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) 
according to the manufacturer’s instructions.
Flow cytometric analysis of CD4+CD25brightCD127–/lowFOXP3+, 
and CLA+CD4+CD25brightFOXP3+ Tregs in peripheral blood
Flow cytometry was utilised to determine cutaneous lymphocy-
te-associated antigen positive (CLA+) CD4+CD25brightFOXP3+ 
Tregs in the blood samples of AD patients and healthy controls. 
Because of the limitation of employable antibodies (regar-
ding colours), first we proved that the gated CD4+CD25bright 
cells were almost exclusively FOXP3 positive and CD127–/low 
(97.3% ± 2.0%) (Fig. 1A). These proportions were calculated 
as the percentage of gated CD4+CD25bright cells. Next, the anti-
CD127 antibody was replaced by anti-CLA 
antibody. CLA positivity was investigated 
on the gated CD4+CD25brightFOXP3+ T cells 
(Fig. 1B, C). Cell surface and intracellular 
staining was carried out according to the 
manufacturer’s instructions. Briefly, after 
PBMC preparation, cells were washed 
in PBS 3 times and cell surface staining 
was performed using CD4-APC or CD4-
FITC, CD127-APC, CLA-FITC (all Becton 
Dickinson, BD Pharmingen, Heidelberg, 
Germany), and CD25-PC5 (Immunotech, 
Marseille, France) antibodies. After cell sur-
face staining, cells were washed in cold Flow 
Cytometry Staining Buffer and re-suspended 
in Fixation/Permeabilisation working solu-
tion (eBioscience, San Diego, CA, USA). 
Samples were incubated at 4°C for 30 min. 
After cells were washed with 1X Permea-
bilisation Buffer (eBioscience, San Diego, 
CA, USA) anti-human FOXP3-PE (clone 
PCH101; eBioscience, San Diego, CA, USA) 
antibody was added to the cell suspension. 
Cells were incubated at 4°C for 30 min in 
the dark. Then, cells were washed with 1X 
Permeabilisation Buffer and re-suspended in 
Flow Cytometry Staining Buffer. Samples 
were analysed on a Becton Dickinson FACS-
Calibur flow cytometer (Becton Dickinson, 
Heidelberg, Germany). Data were analysed 
by CellsQuest software (Becton Dickinson, 
BD Pharmingen, Heidelberg, Germany).
Suppression assay
The CD4+CD25+ Regulatory T-Cell Isola-
tion kit (Miltenyi Biotech GmbH, Bergisch 
Gladbach, Germany) was used to obtain 
Tregs from peripheral blood, as previously 
described in detail (20). The purity of isola-
ted cell populations was above 95% in the 
case of CD4+CD25– cells and 85–95% in 
the case of CD4+CD25+ cells. To detect the 
suppressor activity of CD4+CD25+ Tregs, 
1 × 105 CD4+CD25+ T cells were co-cultured 
with 1 × 105 CD4+CD25− effector T cells in 
200 ml RPMI-1640 in a 96-well microtitre 
plate. For T-cell stimulation, anti-CD3/CD28 
microbeads (Invitrogen Dynal AS, Oslo, 
norway) were applied alone or together with Staphylococcus 
enterotoxin B (SEB) (Sigma-Aldrich, Munich, Germany). For 
the basic experiment, one anti-CD3/CD28 microbead per cell 
and a concentration of 1 pg/ml SEB were used. To prove a 
selective response of Tregs for suppressing SEB-stimulated 
effector T cells, dose-response experiments were utilised. The 
tests were performed first in the presence of 1 pg/ml SEB with 
increasing Treg:Teffector cell ratios (1:2, 1:1, 3:1), and then 
on Treg:Teffector 1:1 cell ratio with increasing concentrations 
of SEB (1 pg/ml, 500 pg/ml, 5 ng/ml). Cell proliferation was 
measured by Ez4U colorimetric cell proliferation assay (Biome-
dica, Vienna, Austria). All of the measurements were performed 
in triplicate and averages were calculated. Suppressor activity 
was determined by an index calculated from the optical den-
sity (OD) values. The OD of mixed CD4+CD25–/CD4+CD25+ 
lymphocyte culture was corrected with the OD of CD4+CD25+ 





-ODCD25+), where MLR stands for mixed 
lymphocyte reaction (20). 
Fig. 1. The identification of regulatory T cells by flow cytometry. CD4 and CD25 cell surface 
molecules were stained with monoclonal antibodies. FOXP3 was quantitated in the CD4+CD25bright 
and CD127–/low– populations (A). CD4 and CD25 cell surface molecules were stained with 
monoclonal antibodies. FOXP3 was quantitated in the CD25bright, CD25low and CD25– populations 
(B). A representative dot-plot from one AD patient and one healthy control displaying the 
percentage of CLA+CD4+CD25brightFOXP3+ Tregs (C).
[AQ1]
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Statistical analysis
Statistical analysis was performed using SPSS 11.0 software 
(SPSS Inc., Chicago, IL, USA). The normal distribution of data 
was tested using the Kolmogorov-Smirnov test. Student’s t-test 
or the nonparametric Mann–Whitney test and kruskal-Wallis 
test were used to compare the data of patients with AD to those 
from healthy controls. The correlation between the percentage of 
CD4+CD25brightFOXP3+ Tregs and CLA+CD4+CD25brightFOXP3+ 
cells as well as IgE levels and the SCORAD index was assessed 
by Pearson’s correlation. Data are presented as mean ± SD, and 
p < 0.05 was considered statistically significant. 
RESULTS
First, CD4+CD25brightCD127–/lowFOXP3+ Tregs were 
determined by flow cytometry in a small number 
of AD patients (n=3). We proved that the gated 
CD4+CD25bright cells were almost exclusively FOXP3 
positive (95.3 ± 3.4%), or CD127–/low (93.4 ± 4.1%) 
(Fig. 1A).  The proportion was calculated as the per-
centage of gated CD4+CD25bright cells (97.3 ± 2.0% of 
the CD4+CD25bright cells were FOXP3+ and CD127–/low). 
The cells with CD4+CD25brightFOXP3+ phenotype were 
examined in further analysis.
Flow cytometric analyses were performed to eva-
luate the frequencies of CD4+CD25brightFOXP3+ Treg 
cells among CD4+ T cells in the peripheral blood of 
AD patients (n = 27) with high IgE levels and age- and 
sex-matched healthy controls (n = 11). After staining for 
CD4, CD25, and CLA cell-surface molecules, FOXP3 
positivity was evaluated in the CD25bright, CD25low and 
CD25– populations (Fig. 1B, C). Our results showed that 
the percentage of CD4+CD25brightFOXP3+ Tregs in total 
CD4+ T cells was significantly elevated in patients with 
AD compared to healthy controls (AD: 3.62 ± 1.55%; 
control: 2.19 ± 0.84%; p = 0.014) (Fig. 2A). To address 
whether the phenotype of Tregs could reflect the ability of 
cells to migrate to the skin, we determined the proportion 
of CLA expressing CD4+CD25brightFOXP3+ Tregs in the 
CD4+ T cells as well as among the peripheral Treg po-
pulation. The frequency of CLA+CD4+CD25brightFOXP3+ 
Tregs was significantly higher in patients with AD com-
pared to healthy controls (AD: 0.78 ± 0.46%; control: 
0.43 ± 0.17%; p = 0.048) (Fig. 2B). The fluorescence 
intensity of CLA on CD4+CD25bright Tregs was higher in 
AD patients as compared to healthy controls (Fig. 1C), 
while there was no difference in the proportion of CLA+ 
Tregs in the Treg population found in AD patients and 
healthy controls (data not shown). 
A statistically significant correlation was found 
between the percentage of CD4+CD25brightFOXP3+ 
Tregs and serum levels of IgE (r = 0.514, p = 0.041, 
Fig. 3A) or SCORAD index (r = 0.584, p = 0.018, Fig. 
3C). We also detected a significant correlation between 
CLA+CD4+CD25brightFOXP3+ Tregs and IgE level 
(r = 0.561, p = 0.024, Fig. 3B) as well as SCORAD 
(r = 0.789, p = 0.0003, Fig. 3D). 
We compared the functional activity of Tregs obtai-
ned from randomly selected AD patients and healthy 
controls. Since CD4+CD25+ cells can 
be either effector or regulatory cells, 
to investigate the suppressor activity 
of CD4+CD25+ T cells, magnetically 
isolated CD4+CD25+ and CD4+CD25– 
T cells were cultured alone and to-
gether in the presence of anti-CD3/
CD28 microbeads, and the effect of 
exotoxin SEB was also tested. In the 
culture of mixed lymphocyte reaction 
of CD4+CD25–/CD4+CD25+ cells, the 
presence of CD4+CD25+ cells caused a 
significant decrease in the proliferation 
of CD4+CD25– effector T cells (Fig. 
4A.). The suppressor function of these 
cells was characterised using a sup-
pressor activity index. The suppressor 
activity of CD4+CD25+ T cells that 
were not subjected to SEB stimulation 
was higher in patients with AD than 
in healthy controls (AD: 4.30 ± 1.79; 
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Fig. 2. Percentage of CD4+CD25brightFOXP3+ Treg cells (A) and 
CLA+CD4+CD25brightFOXP3+ Treg cells (B) of total CD4+ T-cells in AD 
patients (n = 27) compared to healthy controls (n = 11). *p < 0.05, non-
parametric Mann-Whitney and kruskal-Wallis tests.
Fig. 3. Correlation between percentage of Tregs [CD4+CD25brightFOXP3+ (A), percentage of 
CLA+CD4+CD25brightFOXP3+ cells (B)] and IgE serum level. The correlation between percentage 
of Tregs [CD4+CD25brightFOXP3+ (C), CLA+CD4+CD25brightFOXP3+ (D)] and SCORAD index in 
AD patients (n = 16). *p < 0.05, non-parametric Mann-Whitney and kruskal-Wallis tests.
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ference was not significant. However, in the presence of 
SEB, the suppressor activity of CD4+CD25+ T cells was 
significantly decreased in both AD patients and healthy 
controls (AD: 1.79 ± 0.09; control: 1.49 ± 0.10) (Fig. 4B). 
The selective, dose-response reaction of Tregs was pro-
ved first when an increasing Treg:Teffector cell ratio (1:2, 
1:1, 3:1) was studied with constant SEB concentration (1 
pg/ml). The higher the Treg:Teffector ratio was increased, 
the more the Tregs suppressed effector T cells (20–60% 
decrease in the proliferation of effector T cells) (Fig. 
S1A1). When the effect of increasing concentrations of 
SEB (1 pg/ml, 500 pg/ml, 5 ng/ml) was analysed together 
with an equal ratio of Treg:Teffector cells (1:1 ratio), a 
high concentration of SEB (> 500 pg/ml) diminished the 
suppressor activity of Tregs, causing increased prolifera-
tion of effector T cells (Fig. S1B1).
DISCUSSIOn
Regulatory T-cells have an important control fun-
ction in immunologic processes (2, 3, 21). Certain 
T-cell populations with regulatory potentials (TGF-β-
producing Th3 cells, IL-10-producing Tr1 cells, and 
CD4+CD25brightFOXP3+ Tregs) have been described 
(22); however, their proper functions in AD are not yet 
fully elucidated (21).
Allergic, autoimmune, and inflammatory diseases are 
characterised by derailed effector T-cell-mediated im-
mune responses, partly as a consequence of the quanti-
tative and/or functional alteration of Tregs. However, 
because of the heterogeneity of these cells and the lack 
of specific cell markers, the results of different studies 
regarding the characterisation of Tregs in such patholo-
gical conditions are difficult to compare (1, 12, 23–26). 
There is evidence indicating that the percentage of Tregs 
is either normal or increased in the peripheral blood in 
patients suffering from AD; however, there have only 
been a few studies investigating both the number and 
function of Tregs simultaneously (14, 15). 
We have depicted the complex quantitative and 
functional characterisation of Tregs as well as specific 
skin-homing Tregs in AD patients with moderate or se-
vere clinical signs and high IgE levels. Furthermore, for 
the first time we also clarified the correlation between 
CLA+ skin homing Tregs and disease severity, which 
may indicate a more complex pathogenic role of Tregs 
in AD development. 
Previously we have identified high numbers of 
CD4+CD25brightFOXP3+ Tregs in close connection to 
dendritic cells in lesional AD skin and in atopy patch 
test positive biopsies (27). However, elevated numbers 
of CD4+CD25brightFOXP3+ cells in AD patients do not 
necessarily mean that these cells have regulatory fun-
ctions only, since FOXP3 alone is insufficient to deter-
mine the CD4+CD25bright T-cell population with regula-
tory properties in humans (28). In AD, a proportion of 
CD4+CD25brightFOXP3+ and CLA+CD4+CD25brightFOXP3+ 
cells exhibit Th2-like effector function after activation 
by bacterial superantigens (15, 16). To overcome the dif-
ficulty of the inappropriate characterisation of Tregs, we 
first verified the CD4+CD25brightCD127–/lowFOXP3+ T-cell 
population. As a calculated proportion, almost the entire 
percentage of gated CD4+CD25bright cells were FOXP3+ 
and CD127–/low (97.3% ± 2.0%). Henceforth, we identified 
the Treg population as CD4+CD25brightFOXP3+ cells and 
detected significantly increased percentages of these 
cells in the peripheral blood of AD patients, in line with 
a previous result (29). In the next phase, we quantified 
the specific subset of CLA+CD4+CD25brightFOXP3+ skin-
homing Tregs, and described them as also significantly 
increased in the peripheral blood, in accordance with 
previous results (30). 
A significant correlation of CD4+CD25brightFOXP3+ 
Tregs and SCORAD was previously shown, yet serum 
IgE levels and skin-homing Tregs in association with 
disease severity have never been assessed (4, 15, 27). 
Our current report is the first to demonstrate significant 
correlations between the percentage of both Tregs and 
skin-homing Tregs and disease severity, as assessed by 
SCORAD and serum IgE levels in a relatively larger 
AD population.
Previously, conflicting results have been published 
on Treg responses to antigenic stimuli in AD. Tregs 
remained anergic after stimulation by PPD or Der p1 
antigens in both normal controls and AD patients (31). 
Fig. 4. Proliferations of CD4+CD25–, CD4+CD25+ 
and mixed lymphocyte reaction (MLR) of 
CD4+CD25–/CD4+CD25+ cells in the presence 
of anti-CD3/CD28 (in the case of MLR, the 
CD4+CD25+-corrigated optical density is 
displayed) (A). Suppressor activity index of 
CD4+CD25+ regulatory T cells stimulated 
with anti-CD3/CD28 only or together with 
Staphylococcus enterotoxin B (1 pg/ml) in 
patients with atopic dermatitis (AD) (n = 11) 
and in healthy subjects (n = 11) (B). *p < 0.05, 
**p < 0.01 non-parametric Mann-Whitney and 
kruskal-Wallis tests.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1882
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However, another study concluded that Tregs were no 
longer anergic after prior SEB stimulation (14). Our 
functional tests revealed that Tregs, stimulated with 
anti-CD3/CD28, maintained their suppressor activity 
in the peripheral blood of AD patients. However, when 
stimulated with additional SEB, Tregs lost their suppres-
sive ability in both AD patients and normal controls, 
indicating that the primary functional characteristics 
of Tregs in AD are not different from those in healthy 
controls. Thus, we conclude that the main distinctive 
factor in AD is the surrounding environment in the skin 
due to the nearly continuous presence of SEB. 
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Fig. S1. Proliferation of CD4+ effector T cells in AD patients (n = 3) stimulated by anti-CD3/CD28 together with SEB in 
the presence of CD4+CD25+ regulatory T cells in a dose-response experiment. The tests were performed as described in 
details in the “Methods” section. First the proliferation of effector T-cells was studied in the presence of 1 pg/ml SEB 
with increasing Treg:Teffector cell ratios (1:2, 1:1, 3:1) (A), and then on Treg:Teffector 1:1 cell ratio with increasing 
concentrations of SEB (1 pg/ml, 500 pg/ml, 5,000 pg/ml) (B). Cell proliferation was measured by Ez4U colorimetric cell 
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